secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001104659-24-060513
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical Q1 rev $13M (+7% YoY); DFD-29 PDUFA Nov 4, 2024
---------------------------------------------------------------

- Net loss of $10.4M ($0.53 loss per share) vs $10.1M loss ($0.57 loss per share) in Q1 2023.
- Non-GAAP Adjusted EBITDA turned positive at $11K ($0.001 per share) vs negative $5.3M prior year.
- R&D expenses rose to $7.9M from $2.0M due to $4M FDA filing fee and $3M DRL milestone for DFD-29.
- SG&A cut 37% to $8.4M; Qbrexza and Accutane each grew >20% YoY.
- FDA accepted DFD-29 NDA for rosacea; PDUFA target action date November 4, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465924060513/0001104659-24-060513-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465924060513/tm2414271d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-060513

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer